{
    "id": 1967,
    "name": "leiomyosarcoma",
    "source": "DOID",
    "definition": "A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis. [url:http\\://www.cancer.gov/dictionary/?CdrID=46027]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1967",
    "evidence": [
        {
            "id": 4177,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 13% (6/42) of patients with leiomyosarcoma demonstrated clinical benefit with a median progression free survival of 2.2 months when treated with Sprycel (dasatinib) but were below levels considered to result from drug activity (PMID: 26710211).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4408,
                    "pubMedId": 26710211,
                    "title": "SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26710211"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5166,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells treated with BEZ235 in culture and in mouse models demonstrated increased levels of apoptosis and a 42% reduction in tumor volume (PMID: 26952093).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4891,
                    "pubMedId": 26952093,
                    "title": "PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26952093"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5168,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of doxorubicin and BEZ235 produced a synergistic effect in leiomyosarcoma cells both in culture and in mouse models, resulting in apoptotic induction and a 68% reduction in tumor volume (PMID: 26952093).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3763,
                "therapyName": "Aldoxorubicin + BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4891,
                    "pubMedId": 26952093,
                    "title": "PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26952093"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5169,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BKM120 and doxorubicin produced an additive effect when treating leiomyosarcoma cells (PMID: 26952093).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3764,
                "therapyName": "Aldoxorubicin + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4891,
                    "pubMedId": 26952093,
                    "title": "PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26952093"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5538,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 18.6 weeks and median survival of 20.1 months in patients with leiomyosarcoma (PMID: 26970174).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5088,
                    "pubMedId": 26970174,
                    "title": "The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26970174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7296,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Anlotinib (AL-3818) treatment resulted a 12-week progression-free rate of 75%, median progression-free survival of 11 months, an objective response rate of 7.7% (n=26), and a median overall survival of 15 months in patients with leiomyosarcoma (PMID: 29895706; NCT01878448).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 980,
                "therapyName": "Anlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14437,
                    "pubMedId": 29895706,
                    "title": "Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29895706"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8029,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8032,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8313,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment resulted in twelve-week progression free survival in 44% (4/9) of leiomyosarcoma patients (PMID: 27502708).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6602,
                    "pubMedId": 27502708,
                    "title": "Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27502708"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9895,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with LY3039478 resulted in tumor necrosis in a patient with leiomyosarcoma (European Journal of Cancer, Volume 69, S15).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8303,
                    "pubMedId": null,
                    "title": "First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804916326326?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10377,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (3.7 vs 1.8 months), but no difference in overall survival (HR=0.50, p=0.056) compared to placebo in patients with leiomyosarcoma (PMID: 27751846).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8403,
                    "pubMedId": 27751846,
                    "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11087,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 0% (0/10) in patients with leiomyosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9070,
                    "pubMedId": null,
                    "title": "Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.",
                    "url": "http://meetinglibrary.asco.org/record/145286/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12694,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Yondelis (trabectedin) treatment resulted in an improved median progression-free survival of 4.2 months versus 1.5 months with Deticene (dacarbazine) in patients with unresectable or metastatic liposarcoma or leiomyosarcoma (PMID: 28774898; NCT01343277).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3420,
                "therapyName": "Trabectedin",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10606,
                    "pubMedId": 28774898,
                    "title": "FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28774898"
                },
                {
                    "id": 15653,
                    "pubMedId": null,
                    "title": "Yondelis (trabectedin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207953"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13987,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in leiomyosarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053).",
            "molecularProfile": {
                "id": 29900,
                "profileName": "MDM2 amp TP53 loss"
            },
            "therapy": {
                "id": 2113,
                "therapyName": "GDC-0575 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11402,
                    "pubMedId": 29409053,
                    "title": "CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15431,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tasigna (nilotinib) in combination with doxorubicin resulted in 1 short-duration stable disease and 1 progressive disease in 2 patients with leiomyosarcoma, consistent with synergistic growth inhibition in liposarcoma cells in culture and in xenograft models (PMID: 30037815; NCT02587169).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7616,
                "therapyName": "Doxorubicin + Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13269,
                    "pubMedId": 30037815,
                    "title": "Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30037815"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00356031",
            "title": "Bevacizumab and Radiation Therapy for Sarcomas",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01446809",
            "title": "Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1472,
                    "therapyName": "Doxorubicin + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1471,
                    "therapyName": "Doxorubicin + Ifosfamide + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01498484",
            "title": "Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5057,
                    "therapyName": "EB-VST cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02301039",
            "title": "A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02303262",
            "title": "A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3128,
                    "therapyName": "Gemcitabine + Mocetinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584309",
            "title": "Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5153,
                    "therapyName": "Dexrazoxane",
                    "synonyms": null
                },
                {
                    "id": 4140,
                    "therapyName": "Doxorubicin + Olaratumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02601209",
            "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02815995",
            "title": "Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02923778",
            "title": "Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2695,
                    "therapyName": "Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02987959",
            "title": "Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03009201",
            "title": "Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5179,
                    "therapyName": "Doxorubicin + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03074318",
            "title": "Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5444,
                    "therapyName": "Avelumab + Trabectedin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03114527",
            "title": "Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5073,
                    "therapyName": "Everolimus + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03282344",
            "title": "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03437070",
            "title": "Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6774,
                    "therapyName": "Doxorubicin + Olaratumab + Trabectedin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03670069",
            "title": "Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2406,
                    "therapyName": "Itacitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03718091",
            "title": "M6620 (VX-970) in Selected Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2879,
                    "therapyName": "VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719430",
            "title": "APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7428,
                    "therapyName": "APX005M + Doxorubicin + Olaratumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03761095",
            "title": "A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7611,
                    "therapyName": "Dacarbazine + PTC596",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03851614",
            "title": "Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2895,
                    "therapyName": "Cediranib + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03899805",
            "title": "A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3080,
                    "therapyName": "Eribulin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04028063",
            "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9314,
                    "therapyName": "AGEN1884 + AGEN2034 + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04076579",
            "title": "Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7458,
                    "therapyName": "Olaparib + Trabectedin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04200443",
            "title": "Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9094,
                    "therapyName": "Cabozantinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04242238",
            "title": "Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9289,
                    "therapyName": "Avelumab + DCC-3014",
                    "synonyms": null
                }
            ]
        }
    ]
}